Synopsis Irbesartan inhibits the activity of angiotensin II (AII) via specific, selective non-
competitive antagonism of the AII receptor subtype I (AT 1) which mediates most of the …

The safety, pharmacokinetics, and pharmacodynamics of single and multiple doses of the
angiotensin II (AII) AT1 blocker irbesartan were assessed in healthy subjects. In this single …

Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively
studied in the Bristol-Myers Squibb/Sanofi clinical development program. As shown in seven …

Irbesartan interrupts the renin-angiotensin system via selective blockade of the angiotensin
II subtype 1 receptor; the latter being responsible for the pressor related effects of …

This article reviews the pharmacokinetics and pharmacodynamics of angiotensin II (AII)
receptor antagonists (AIIRA), with particular focus on the novel compound irbesartan …

The recently developed and marketed angiotensin II type 1 (AT1) receptor blockers (ARBs)
have demonstrated efficacy equivalent to that of other leading classes of antihypertensive …

Results of recent studies have shown that blood pressure control is achieved in less than
half of hypertensive patients taking currently available antihypertensive agents [1–3]. Given …

Two multicenter, double-blind, placebo-controlled, parallel group studies were conducted to
evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of the angiotensin II …

Results of eight multicenter, randomized, placebo-controlled, double-blind, parallel-group
studies were pooled to assess the efficacy of the angiotensin II–receptor blocker irbesartan …

We studied the hemodynamic, neurohumoral, and biochemical effects of the novel
angiotensin type 1 (AT1) receptor antagonist irbesartan in 86 untreated patients with …